ReviewTissue engineering. Part B, Reviews2022
Engineering Three-Dimensional Vascularized Cardiac Tissues.
Review in Tissue engineering. Part B, Reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- 3D bioprinting of microfluidic systems for cardiac regenerative medicine: from biofabrication to organ-on-a-chip.Journal of biological engineering · 2026Review
- Vascularized Cardiac Tissue Engineering: From Advances in Biofabrication to Translational Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Advancing Congenital Heart Defect Treatments: Synergistic Approaches with Stem Cells and Functional Scaffolds.Stem cell reviews and reports · 2026Review
- Tapered Pillar Design for High-Precision Force Readout in Miniaturized Engineered Heart Tissues From Human Pluripotent Stem Cells.Advanced healthcare materials · 2025Article
- Current status and new horizons in stem cell therapy in cardiovascular regenerative medicine (CaVaReM): an update.European journal of medical research · 2025Review
- Effect of Biomedical Hydrogels on Exercise-induced Muscle Damage: A Narrative Review.Current medicinal chemistry · 2025Review
- Decoding congenital heart disease: a multi-omic framework for cardiac lineage and regulatory dysfunction.Frontiers in cell and developmental biology · 2025Review
- Advancing 3D Engineered In Vitro Models for Heart Failure Research: Key Features and Considerations.Bioengineering (Basel, Switzerland) · 2024Review
- NOS3 regulates angiogenic potential of human induced pluripotent stem cell-derived endothelial cells.Biochemistry and biophysics reports · 2024Article
- Primitive macrophages enable long-term vascularization of human heart-on-a-chip platforms.Cell stem cell · 2024Article
- Recent Advances in Hydrogel-Based 3D Bioprinting and Its Potential Application in the Treatment of Congenital Heart Disease.Biomolecules · 2024Review
- Stem cells and bio scaffolds for the treatment of cardiovascular diseases: new insights.Frontiers in cell and developmental biology · 2024Review
- Advancements in tissue engineering for cardiovascular health: a biomedical engineering perspective.Frontiers in bioengineering and biotechnology · 2024Review
- Comparative Analysis of Heart Regeneration: Searching for the Key to Heal the Heart-Part I: Experimental Injury Models to Study Cardiac Regeneration.Journal of cardiovascular development and disease · 2023Review
- Biofabrication of functional bone tissue: defining tissue-engineered scaffolds from nature.Frontiers in bioengineering and biotechnology · 2023Review
- Myocardial infarction from a tissue engineering and regenerative medicine point of view: A comprehensive review on models and treatments.Biophysics reviews · 2022Review
- A Change of Heart: Human Cardiac Tissue Engineering as a Platform for Drug Development.Current cardiology reports · 2022Review
- Biomaterials-based Approaches for Cardiac Regeneration.Korean circulation journal · 2021Review
- Regenerative and molecular therapies for myocardial repair (Review).Medicine internationalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Heart disease is one of the largest burdens to human health worldwide and has very limited therapeutic options. Engineered three-dimensional (3D) vascularized cardiac tissues have shown promise in rescuing cardiac function in diseased hearts and may serve as a whole organ replacement in the future. One of the major obstacles in reconstructing these thick myocardial tissues to a clinically applicable scale is the integration of functional vascular networks capable of providing oxygen and nutrients throughout whole engineered constructs. Without perfusion of oxygen and nutrient flow throughout the entire engineered tissue not only is tissue viability compromised, but also overall tissue functionality is lost. There are many supporting technologies and approaches that have been developed to create vascular networks such as 3D bioprinting, co-culturing hydrogels, and incorporation of soluble angiogenic factors. In this state-of-the-art review, we discuss some of the most current engineered vascular cardiac tissues reported in the literature and future directions in the field. Impact statement The field of cardiac tissue engineering is rapidly evolving and is now closer than ever to having engineered tissue models capable of predicting preclinical responses to therapeutics, modeling diseases, and being used as a means of rescuing cardiac function following injuries to the native myocardium. However, a major obstacle of engineering thick cardiac tissue remains to be the integration of functional vasculature. In this review, we highlight seminal and recently published works that have influenced and pushed the field of cardiac tissue engineering toward achieving vascularized functional tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.